19:05 , Jun 1, 2018 |  BC Week In Review  |  Company News

Crescendo grants Zai rights to psoriasis antibody

Crescendo Biologics Ltd. (Cambridge, U.K.) granted Zai Lab Ltd. (NASDAQ:ZLAB) exclusive, worldwide rights to an undisclosed antibody based on its Humabody platform. Crescendo received an upfront payment and is eligible for milestones and royalties. Zai and...
18:43 , May 30, 2018 |  BC Extra  |  Company News

Crescendo grants Zai rights to psoriasis antibody

Crescendo Biologics Ltd. (Cambridge, U.K.) granted Zai Lab Ltd. (NASDAQ:ZLAB) exclusive, worldwide rights to an undisclosed antibody based on its Humabody platform. Crescendo received an upfront payment and is eligible for milestones and royalties. Zai and...
19:06 , May 4, 2018 |  BC Week In Review  |  Financial News

Andera leads Crescendo’s $70M series B

Crescendo Biologics Ltd. (Cambridge, U.K.) raised $70 million in a series B round led by new investor Andera Partners (formerly Edmond de Rothschild Investment Partners). Fellow new investor Quan Capital joined existing investors Sofinnova Partners,...
21:31 , Apr 30, 2018 |  BC Extra  |  Financial News

Andera leads Crescendo’s $70M series B

Crescendo Biologics Ltd. (Cambridge, U.K.) raised $70 million in a series B round led by new investor Andera Partners (formerly Edmond de Rothschild Investment Partners). Fellow new investor Quan Capital joined existing investors Sofinnova Partners,...
00:57 , Feb 14, 2018 |  BC Innovations  |  Distillery Techniques

Assays and screens

TECHNOLOGY: Cellular assays; high throughput screening A high throughput yeast-based method of antibody screening could help identify therapeutic antibodies in human blood. The method involves three steps: engineering a yeast strain with cell-surface expression of a...
21:03 , Apr 6, 2017 |  BC Innovations  |  Translation in Brief

Humabodies come of age

With its transgenic mouse platform now in place, a deal with Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) in hand and a new CSO announced this week, Crescendo Biologics Ltd. has pivoted from technology optimization to therapeutic...
00:38 , Mar 23, 2017 |  BC Innovations  |  Distillery Techniques

Assays and screens; drug platforms

TECHNOLOGY: Cellular assays; peptides A genomic and proteomic screening method could identify neoantigens as personalized immunotherapy targets for cancer. The method involved collecting tumor and non-tumor tissue samples from a patient; immunoprecipitating human leukocyte antigen class...
23:30 , Mar 22, 2017 |  BC Extra  |  Clinical News

Stanford neoantigen pipeline finds Ig targets in lymphoma

In a study published Wednesday in Nature, a Stanford University team's neoantigen identification pipeline showed patient-specific, or "idiotypic," immunoglobulin peptides were presented on human leukocyte antigen (HLA) class II molecules in mantle cell lymphoma (MCL)...
07:00 , Oct 20, 2008 |  BC Week In Review  |  Clinical News

Campath alemtuzumab: Phase II data

In an open-label, U.S. Phase II trial in 30 untreated, high-risk CLL patients, Campath and Rituxan rituximab combination therapy resulted in 27 responses (90%) at 2 months after completion of 4 weeks of therapy,...
07:00 , Oct 20, 2008 |  BC Week In Review  |  Clinical News

Rituxan rituximab: Phase II data

In an open-label, U.S. Phase II trial in 30 untreated, high-risk CLL patients, Campath alemtuzumab and Rituxan combination therapy resulted in 27 responses (90%) at 2 months after completion of 4 weeks of therapy,...